[
  {
    "ts": null,
    "headline": "Stock Market Today: Nasdaq Surges On Tech Spike; These Defense Stocks Fall Amid Ukraine Progress (Live Coverage)",
    "summary": "The Dow Jones index and the Nasdaq rose on the stock market today, with Tesla and Alphabet among AI stocks jumping. Health stocks tested entries.",
    "url": "https://finnhub.io/api/news?id=c607618f2af4a40052d36008baadd6f292ee13e988c796371e291e14f35248ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764011020,
      "headline": "Stock Market Today: Nasdaq Surges On Tech Spike; These Defense Stocks Fall Amid Ukraine Progress (Live Coverage)",
      "id": 137592601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones index and the Nasdaq rose on the stock market today, with Tesla and Alphabet among AI stocks jumping. Health stocks tested entries.",
      "url": "https://finnhub.io/api/news?id=c607618f2af4a40052d36008baadd6f292ee13e988c796371e291e14f35248ef"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
    "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car",
    "url": "https://finnhub.io/api/news?id=23dcd43d4d13da9d5009b05da5a2c895470d9290d173e98ec9ea32586b5a76e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764009981,
      "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
      "id": 137592695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car",
      "url": "https://finnhub.io/api/news?id=23dcd43d4d13da9d5009b05da5a2c895470d9290d173e98ec9ea32586b5a76e6"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow, Nasdaq Up As Alphabet, Tesla Jump; These Health Plays Test Entries (Live Coverage)",
    "summary": "The Dow Jones index and the Nasdaq rose on the stock market today, with Tesla and Alphabet among AI stocks jumping. Health stock tested entries.",
    "url": "https://finnhub.io/api/news?id=1be78d575ac99d4ec0f939f4d78fac9c8abceae69847c82c79933cc0bd0f6443",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764006136,
      "headline": "Stock Market Today: Dow, Nasdaq Up As Alphabet, Tesla Jump; These Health Plays Test Entries (Live Coverage)",
      "id": 137591212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones index and the Nasdaq rose on the stock market today, with Tesla and Alphabet among AI stocks jumping. Health stock tested entries.",
      "url": "https://finnhub.io/api/news?id=1be78d575ac99d4ec0f939f4d78fac9c8abceae69847c82c79933cc0bd0f6443"
    }
  },
  {
    "ts": null,
    "headline": "This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?",
    "summary": "The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.",
    "url": "https://finnhub.io/api/news?id=a7399bb3673bcda91cd8060e981aae1d2cb64c0608196c8f3416e42cba8a5f96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764005749,
      "headline": "This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?",
      "id": 137592696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.",
      "url": "https://finnhub.io/api/news?id=a7399bb3673bcda91cd8060e981aae1d2cb64c0608196c8f3416e42cba8a5f96"
    }
  },
  {
    "ts": null,
    "headline": "Moderna is the S&P 500's most shorted stock: Here's why",
    "summary": "President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.",
    "url": "https://finnhub.io/api/news?id=074ab3f0f60823d93da8c1893319c62e7dc0649084f6b785072526aaabcf9eaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764005415,
      "headline": "Moderna is the S&P 500's most shorted stock: Here's why",
      "id": 137591348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.",
      "url": "https://finnhub.io/api/news?id=074ab3f0f60823d93da8c1893319c62e7dc0649084f6b785072526aaabcf9eaa"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.",
    "url": "https://finnhub.io/api/news?id=0ccb02c5de26d2eaddba29a487884fbf0e5688e4643155469c7b118713397f65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764003600,
      "headline": "Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting",
      "id": 137591349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.",
      "url": "https://finnhub.io/api/news?id=0ccb02c5de26d2eaddba29a487884fbf0e5688e4643155469c7b118713397f65"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club",
    "summary": "Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.",
    "url": "https://finnhub.io/api/news?id=1394096dccdb101ba1ff5e89cb68d83bc85b2489afecf020a5a23d17274228b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764003574,
      "headline": "Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club",
      "id": 137591224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.",
      "url": "https://finnhub.io/api/news?id=1394096dccdb101ba1ff5e89cb68d83bc85b2489afecf020a5a23d17274228b2"
    }
  },
  {
    "ts": null,
    "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
    "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
    "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764002785,
      "headline": "Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock",
      "id": 137591351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.",
      "url": "https://finnhub.io/api/news?id=2b0351106e5d56c3528387343c5f0c530bc138273a1eab30d887f00ab014f53e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.",
    "summary": "The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.",
    "url": "https://finnhub.io/api/news?id=8db803eabb3897db25a0b11f419e9bd28d0f8ef63d1ed0b9172421bcb672532d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764002040,
      "headline": "Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.",
      "id": 137591352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.",
      "url": "https://finnhub.io/api/news?id=8db803eabb3897db25a0b11f419e9bd28d0f8ef63d1ed0b9172421bcb672532d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Benefits From 'Broadening' GLP-1 Market, Morgan Stanley Says",
    "summary": "Eli Lilly (LLY) is benefiting from the \"broadening\" GLP-1 market for obesity and type-2 diabetes, Mo",
    "url": "https://finnhub.io/api/news?id=f23ce9c9a622b90ad62dbca8665fc0feb9f740ee5de67d7421906cad67515982",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764000569,
      "headline": "Eli Lilly Benefits From 'Broadening' GLP-1 Market, Morgan Stanley Says",
      "id": 137591353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is benefiting from the \"broadening\" GLP-1 market for obesity and type-2 diabetes, Mo",
      "url": "https://finnhub.io/api/news?id=f23ce9c9a622b90ad62dbca8665fc0feb9f740ee5de67d7421906cad67515982"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's",
    "summary": "Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease.  Novo Nordisk stock recently stood about 9% lower, on pace for its lowest close since July 2021, according to Dow Jones Market Data.  The shares have tumbled by nearly three-quarters since hitting a peak at 1,028 Danish kroner in June last year.",
    "url": "https://finnhub.io/api/news?id=210221d3137aa5fd6468747a39dbcc020dd73524b7ebdb0f2cef4100013a6605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763994749,
      "headline": "Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's",
      "id": 137591354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease.  Novo Nordisk stock recently stood about 9% lower, on pace for its lowest close since July 2021, according to Dow Jones Market Data.  The shares have tumbled by nearly three-quarters since hitting a peak at 1,028 Danish kroner in June last year.",
      "url": "https://finnhub.io/api/news?id=210221d3137aa5fd6468747a39dbcc020dd73524b7ebdb0f2cef4100013a6605"
    }
  },
  {
    "ts": null,
    "headline": "Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps",
    "summary": "Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.",
    "url": "https://finnhub.io/api/news?id=94f7b64989500bd7e1381721cd92f277e57f42e0761ae5339a77dc699987aa86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763994209,
      "headline": "Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps",
      "id": 137591355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.",
      "url": "https://finnhub.io/api/news?id=94f7b64989500bd7e1381721cd92f277e57f42e0761ae5339a77dc699987aa86"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials",
    "summary": "A pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.",
    "url": "https://finnhub.io/api/news?id=6f83c235b639b7c27205a69efc1a923c872b6875d9ee9c9ccf82d7b7b21b658f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763991480,
      "headline": "Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials",
      "id": 137591356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.",
      "url": "https://finnhub.io/api/news?id=6f83c235b639b7c27205a69efc1a923c872b6875d9ee9c9ccf82d7b7b21b658f"
    }
  },
  {
    "ts": null,
    "headline": "Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?",
    "summary": "Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.",
    "url": "https://finnhub.io/api/news?id=00c663ca515c06e1b960f55d66c08375918fa1b34e4fa473065bb0c3c7d8dba8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763991000,
      "headline": "Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?",
      "id": 137591357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.",
      "url": "https://finnhub.io/api/news?id=00c663ca515c06e1b960f55d66c08375918fa1b34e4fa473065bb0c3c7d8dba8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
    "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
    "url": "https://finnhub.io/api/news?id=923dcc45527f789e33996e4c3cc174572fef8802d93778210e16f31c20a18743",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763990394,
      "headline": "Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps",
      "id": 137589129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk reported Monday that a Ozempic pill failed to slow the progression of Alzheimer's in two big studies. Novo dived, Eli Lilly fell. Biogen rose.",
      "url": "https://finnhub.io/api/news?id=923dcc45527f789e33996e4c3cc174572fef8802d93778210e16f31c20a18743"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Jones Rises; Google Pops On Salesforce Praise, Novo Nordisk Dives",
    "summary": "Futures rose Monday. Google popped amid Salesforce CEO Marc Benioff's praise for AI model Gemini 3. Novo Nordisk dived on Alzheimer's trial data.",
    "url": "https://finnhub.io/api/news?id=1713a63a213910d70e580be329b7217c1d094b7eeeab080ffbb78c397655cc5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763991036,
      "headline": "Stock Market Today: Dow Jones Rises; Google Pops On Salesforce Praise, Novo Nordisk Dives",
      "id": 137589046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures rose Monday. Google popped amid Salesforce CEO Marc Benioff's praise for AI model Gemini 3. Novo Nordisk dived on Alzheimer's trial data.",
      "url": "https://finnhub.io/api/news?id=1713a63a213910d70e580be329b7217c1d094b7eeeab080ffbb78c397655cc5f"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
    "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
    "url": "https://finnhub.io/api/news?id=3c8c3fead44bf2e2ef33b498d705b3e6657d864f51350c2987919c7fc45ea91f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763990160,
      "headline": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
      "id": 137591358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
      "url": "https://finnhub.io/api/news?id=3c8c3fead44bf2e2ef33b498d705b3e6657d864f51350c2987919c7fc45ea91f"
    }
  },
  {
    "ts": null,
    "headline": "Ukraine peace, robotaxis and pharma: what's moving stocks",
    "summary": "The selloff in European defense stocks (BA.L, RHM.DE, HO.PA, BAB.L) deepens as hopes grow around a peace deal draft for Ukraine and Russia. China's robotaxi firm WeRide (WRD) rallies on a massive revenue jump - even though the firm is still burning cash. In pharma, after Eli Lilly (LLY) hit $1 trillion: Bayer (BAYN.DE) stock flies, Novo Nordisk (NVO, NOVO-B.CO) tanks. For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finnhub.io/api/news?id=ede938a48ddc6a8acc2f9aaaa15b28da1f1ccb3117e9d44bd797d420887282ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763989600,
      "headline": "Ukraine peace, robotaxis and pharma: what's moving stocks",
      "id": 137589131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The selloff in European defense stocks (BA.L, RHM.DE, HO.PA, BAB.L) deepens as hopes grow around a peace deal draft for Ukraine and Russia. China's robotaxi firm WeRide (WRD) rallies on a massive revenue jump - even though the firm is still burning cash. In pharma, after Eli Lilly (LLY) hit $1 trillion: Bayer (BAYN.DE) stock flies, Novo Nordisk (NVO, NOVO-B.CO) tanks. For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
      "url": "https://finnhub.io/api/news?id=ede938a48ddc6a8acc2f9aaaa15b28da1f1ccb3117e9d44bd797d420887282ab"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Price Falls After Ozempic Fails to Slow Alzheimer's",
    "summary": "Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease.    Novo Nordisk stock recently stood about 10% lower, on pace for its lowest close since July 2021, according to Dow Jones Market Data.",
    "url": "https://finnhub.io/api/news?id=470bd467d148179d35598aa498f06d2d3d104ad13fe2734aaaac98f260ccf375",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763986582,
      "headline": "Novo Nordisk Stock Price Falls After Ozempic Fails to Slow Alzheimer's",
      "id": 137589133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease.    Novo Nordisk stock recently stood about 10% lower, on pace for its lowest close since July 2021, according to Dow Jones Market Data.",
      "url": "https://finnhub.io/api/news?id=470bd467d148179d35598aa498f06d2d3d104ad13fe2734aaaac98f260ccf375"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in",
    "summary": "Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.",
    "url": "https://finnhub.io/api/news?id=444fed74d38cd8f0eee5d54cbb6b46521a28a543d2c10f06887ad4e895d84956",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763985600,
      "headline": "Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in",
      "id": 137589134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.",
      "url": "https://finnhub.io/api/news?id=444fed74d38cd8f0eee5d54cbb6b46521a28a543d2c10f06887ad4e895d84956"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Tesla, Alphabet, Alibaba, Strategy, Eli Lilly, and More",
    "summary": "Stock futures were rising Monday with investors hopeful that economic data due this week will strengthen the case for the Federal Reserve to cut interest rates next month.  CEO Elon Musk said Sunday in a post on X that the electric-vehicle maker already had designed several million artificial-intelligence chips for its cars and data centers.  Tesla is close to finishing its AI5 chip, has started work on its AI6 chip, and is aiming to bring a new chip to volume production every 12 months, Musk added.",
    "url": "https://finnhub.io/api/news?id=637808b4d0e069b36ad8d822ebf7210301bf8ce97925137bedcc89d648c04d3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763981580,
      "headline": "These Stocks Are Moving the Most Today: Tesla, Alphabet, Alibaba, Strategy, Eli Lilly, and More",
      "id": 137589028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock futures were rising Monday with investors hopeful that economic data due this week will strengthen the case for the Federal Reserve to cut interest rates next month.  CEO Elon Musk said Sunday in a post on X that the electric-vehicle maker already had designed several million artificial-intelligence chips for its cars and data centers.  Tesla is close to finishing its AI5 chip, has started work on its AI6 chip, and is aiming to bring a new chip to volume production every 12 months, Musk added.",
      "url": "https://finnhub.io/api/news?id=637808b4d0e069b36ad8d822ebf7210301bf8ce97925137bedcc89d648c04d3e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Semaglutide's Success In Alzheimer's Was  Unlikely",
    "summary": "Novo Nordisk A/S's Alzheimer's drug failed trials, impacting shares. Click to see why NVO remains a value stock with multiple growth opportunities.",
    "url": "https://finnhub.io/api/news?id=f269ff0a5643b4005ff44c31633c3c856b6203ca73ad756ef4154bacacd2ad4f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763979616,
      "headline": "Novo Nordisk: Semaglutide's Success In Alzheimer's Was  Unlikely",
      "id": 137590248,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1279694881/image_1279694881.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S's Alzheimer's drug failed trials, impacting shares. Click to see why NVO remains a value stock with multiple growth opportunities.",
      "url": "https://finnhub.io/api/news?id=f269ff0a5643b4005ff44c31633c3c856b6203ca73ad756ef4154bacacd2ad4f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares plunge after Alzheimer's drug trial fails to hit key target",
    "summary": "Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal.",
    "url": "https://finnhub.io/api/news?id=fe0d2bb1dcd6197f56c7ca541276872d09bf9d22b8550b1bf082818e17649254",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763966481,
      "headline": "Novo Nordisk shares plunge after Alzheimer's drug trial fails to hit key target",
      "id": 137590978,
      "image": "https://image.cnbcfm.com/api/v1/image/108178404-17537973702025-07-29t124507z_1311503085_rc2bmfaaroie_rtrmadp_0_novo-nordisk.jpeg?v=1753891974&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal. ",
      "url": "https://finnhub.io/api/news?id=fe0d2bb1dcd6197f56c7ca541276872d09bf9d22b8550b1bf082818e17649254"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound",
    "summary": "Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock is upgraded to strong buy.",
    "url": "https://finnhub.io/api/news?id=1e1e34c621ea885ed837a572e90713b95609763dc8eca28b3d06efb598bc7bb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763965869,
      "headline": "Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound",
      "id": 137588393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244717379/image_2244717379.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock is upgraded to strong buy.",
      "url": "https://finnhub.io/api/news?id=1e1e34c621ea885ed837a572e90713b95609763dc8eca28b3d06efb598bc7bb2"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures, Bitcoin Rise; Nvidia, Apple, Eli Lilly In Focus",
    "summary": "The stock market needs to show a lot of strength after damaging recent losses. Watch Nvidia, Apple and Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=4c4d4b34c114038a8f114451bb15b71abd7a14d52b6d61271585747106392fa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763957103,
      "headline": "Dow Jones Futures, Bitcoin Rise; Nvidia, Apple, Eli Lilly In Focus",
      "id": 137586555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market needs to show a lot of strength after damaging recent losses. Watch Nvidia, Apple and Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=4c4d4b34c114038a8f114451bb15b71abd7a14d52b6d61271585747106392fa5"
    }
  },
  {
    "ts": null,
    "headline": "Don't Buy This Dip: It's Black Friday In The Equity Market",
    "summary": "NVDA shows strong results with volatility, liquidity pressure, market softness, rally hopes, and a strategy around the 200-day. Read why SPX is a sell.",
    "url": "https://finnhub.io/api/news?id=afcdff1a73c12737d4f2762342979d89f313b608e3fd26022a219994b2ed82cb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763954562,
      "headline": "Don't Buy This Dip: It's Black Friday In The Equity Market",
      "id": 137587609,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213574691/image_1213574691.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "NVDA shows strong results with volatility, liquidity pressure, market softness, rally hopes, and a strategy around the 200-day. Read why SPX is a sell.",
      "url": "https://finnhub.io/api/news?id=afcdff1a73c12737d4f2762342979d89f313b608e3fd26022a219994b2ed82cb"
    }
  },
  {
    "ts": null,
    "headline": "CNBC Daily Open: A turnaround in sentiment for U.S. markets may be in the cards",
    "summary": "New York Federal Reserve President John Williams' suggestion that a rate cut could be on the table lifted U.S. markets on Friday.",
    "url": "https://finnhub.io/api/news?id=1b1d25b0c05d5c0d9ea21b00b0e009bd42aef11757401cf7db522511efc0d604",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763951401,
      "headline": "CNBC Daily Open: A turnaround in sentiment for U.S. markets may be in the cards",
      "id": 137590979,
      "image": "https://image.cnbcfm.com/api/v1/image/108230279-1763764172605-gettyimages-2247843141-anotherday150731108_ssx73a5v.jpeg?v=1763764287&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "New York Federal Reserve President John Williams' suggestion that a rate cut could be on the table lifted U.S. markets on Friday.",
      "url": "https://finnhub.io/api/news?id=1b1d25b0c05d5c0d9ea21b00b0e009bd42aef11757401cf7db522511efc0d604"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks.",
    "summary": "These Magnificent Seven players are well-positioned to benefit in the AI boom.",
    "url": "https://finnhub.io/api/news?id=f5544db38a556f356484feaaf9473a85e36ae57ecba36f0963b3971ba551561c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763943000,
      "headline": "Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks.",
      "id": 137586559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These Magnificent Seven players are well-positioned to benefit in the AI boom.",
      "url": "https://finnhub.io/api/news?id=f5544db38a556f356484feaaf9473a85e36ae57ecba36f0963b3971ba551561c"
    }
  }
]